Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The primary objective is to evaluate in a double-blinded (neither physician nor participant
      knows the treatment that the participant receives), fashion the taste of different
      JNJ-53718678 oral liquid formulations as compared to the reference formulation (JNJ-53718678,
      10 milligram/milliliter oral solution without sweetener/flavor).
    

Detailed description: 
      This is a Phase 1, double-blind, randomized (participants taste the same groups of drugs
      [formulations] but in random order), single-center trial in healthy adult participants. The
      study will include 2 Sessions of 1 day, 1) Session 1, in which participants will receive 6
      JNJ-53718678 oral solutions (1 reference and 5 different formulations) sequentially in a
      randomized order, Scoring of the taste will be done via a questionnaire designed for this
      purpose; 2) Session 2, within approximately a timeframe of 7 to 14 days after completion of
      Session 1, participants will taste 2 best scoring tastes coming out of Session 1. The study
      will consist of a screening phase of approximately 2 weeks, treatment phase of approximately
      2 weeks and a post-treatment follow-up phase of 10 days after completion of the last Session.
      The total study duration for each participant will be approximately 6 weeks.
    

Intervention name(s): Formulation A; Formulation B; Formulation C; Formulation D; Formulation E; Formulation F; Formulation M1; Formulation M2; Formulation M3; Formulation N1; Formulation N2; Formulation N3
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.; 10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.; 10 mg/mL oral solution containing 10 mg/mL sucralose.; 10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.; 10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.; 10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.; Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).; Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).; Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).; Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).; Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).; Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
Other intervention name(s): JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678; JNJ-53718678
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Other
Keywords: Healthy; JNJ-53718678